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The present study describes supportive care (SC) in patients with advanced non-small-cell lung cancer (NSCLC), evaluating whether
it is affected by concomitant chemotherapy, patient’s performance status (PS) and age. Data of patients enrolled in three randomised
trials of first-line chemotherapy, conducted between 1996 and 2001, were pooled. The analysis was limited to the first three cycles of
treatment. Supportive care data were available for 1185 out of 1312 (90%) enrolled patients. Gastrointestinal drugs (45.7%),
corticosteroids (33.4%) and analgesics (23.8%) were the most frequently observed categories. The mean number of drugs per patient
was 2.43; 538 patients (45.4%) assumed three or more supportive drugs. Vinorelbine does not produce substantial variations in the
SC pattern, while cisplatin-based treatment requires an overall higher number of supportive drugs, with higher use of antiemetics
(41 vs 27%) and antianaemics (10 vs 4%). Patients with worse PS are more exposed to corticosteroids (42 vs 30%). Elderly patients
require drugs against concomitant diseases significantly more than adults (20 vs 7%) and are less frequently exposed to antiemetics
(12 vs 27%). In conclusion, polypharmacotherapy is a relevant issue in patients with advanced NSCLC. Chemotherapy does not
remarkably affect the pattern of SC, except for some drugs against side effects. Elderly patients assume more drugs for concomitant
diseases and receive less antiemetics than adults.
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Data from meta-analysis (Non-small Cell Lung Cancer Collabora-
tive Group, 1995) show a slight but significant median survival
advantage (6 weeks) for platinum-containing chemotherapy in the
treatment of patients with advanced non-small-cell lung cancer
(NSCLC). Some benefit was also shown for chemotherapy in
elderly patients, in terms of both survival and quality of life (The
ELVIS group, 1999).
Based on these results, although the efficacy of currently
available chemotherapy is far from being satisfactory, the majority
of patients diagnosed with advanced NSCLC are offered che-
motherapy. In addition to antineoplastic drugs, a variable number
of different drugs are given as supportive care (SC), that is, ‘every
treatment given to prevent, control or relieve complications and
side effects and to improve the patient’s comfort and quality of life
of people who have cancer’ (National Cancer Institute Dictionary,
2002).
The concomitant assumption of several drugs leads to obvious
pharmacoeconomic and practical problems of compliance for
patients, and raises important safety issues. Pharmacological
interactions are identified as one of the eight ‘drug-related
problems’ (Strand et al, 1990) and are a common and serious
consequence of polypharmacotherapy (Cadieux, 1989). At a
pharmacokinetic level, one drug can interfere with absorption,
distribution, metabolism and excretion of another drug. Moreover,
the assumption of a high number of drugs can reduce patients’
compliance and, more dangerously, induce errors of dose and
timing of assumption (Hulka et al, 1975). All of these problems can
give rise to toxic effects, especially when drugs with a low
therapeutic index, like cytotoxic drugs, are used.
The present study has two main aims: first, to give a picture of
the number and variety of supportive drugs assumed by patients
with advanced NSCLC during chemotherapy, and, second, to
assess the impact of chemotherapy, patient’s performance status
(PS) and patient’s age on the assumption of SC.
MATERIALS AND METHODS
Patients
Patients with advanced NSCLC who participated in three
randomised clinical trials (The ELVIS group, 1999; Gridelli et al,
2003a,b) performed by our cooperative group between 1996 and
2001 were selected for this study. All three studies were approved
by Ethical Committees, and all patients gave written informed
consent. They had stage IV or IIIB (with supraclavicular metastatic
nodes or malignant pleural effusion) disease and a baseline PS not
worse than 2, according to the ECOG scale (Oken et al, 1982).
In the ELVIS study (Elderly) Lung cancer Vinorelbine Italian
Study (The ELVIS group, 1999), vinorelbine was compared with SC
alone in patients X70 years. Vinorelbine was given 30mgm
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ldays 1 and 8 every 3 weeks, for six cycles. The primary end point
was quality of life. Recruitment started in April 1996, and overall
191 patients were randomised.
The MILES study (Multicentre Italian Lung cancer in the Elderly
Study (Gridelli et al, 2003b)) was conducted in the same subset of
patients of the ELVIS trial, and compared the combination of
vinorelbine and gemcitabine vs the two single drugs. Patients were
randomly assigned vinorelbine (30mgm
 2), gemcitabine
(1200mgm
 2) or vinorelbine (25mgm
 2) plus gemcitabine
(1000mgm
 2). All treatments were delivered on days 1 and 8
every 3 weeks for six cycles. The primary end point was overall
survival. In all, 707 patients were randomised between December
1997 and November 2000.
The GEMVIN3 study (Gridelli et al, 2003a) was conducted with
adult (o70 years) patients, randomly assigned vinorelbine
(25mgm
 2, days 1 and 8) plus gemcitabine (1000mgm
 2, days
1 and 8) or cisplatin-based chemotherapy: cisplatin (80mgm
 2,
day 1) either plus gemcitabine (1200mgm
 2, days 1 and 8) or plus
vinorelbine (30mgm
 2, days 1 and 8) for six cycles of 21 days. The
study aimed to assess whether the combination of gemcitabine and
vinorelbine improved quality of life, without shortening survival,
compared to standard platinum-containing regimens. Accrual
started in Italy in October 1998, and in Canada in May 1999.
Overall, 503 patients (414 in Italy) were randomised, between
October 1998 and March 2001. In this analysis, only Italian
patients are considered.
Protocol requirements and data collection on SC
In all the three trials, investigators were free to choose SC. Each
protocol reported only general guidelines about the modalities of
administration of the main categories of supportive drugs.
The three-step WHO ladder (World Health Organization, 1996)
was recommended for treatment of pain. In case of febrile
infections, the association of a third-generation cephalosporin and
an aminoglycoside was recommended, with modifications deter-
mined by the results of haemoculture. In case of grade 4
neutropenia, prophylactic administration of a quinolone was
recommended and use of colony-stimulating factors (CSF) was
allowed until resolution of toxicity. No prophylactic administra-
tion of CSF was mandated by protocol. Corticosteroids were
recommended for hypercalcaemia, respiratory failure and intra-
cranial hypertension.
The three studies had the same Case Report Form for SC. Data
were collected from the starting date of chemotherapy until
interruption, for up to seven drugs in each cycle of chemotherapy
(corresponding to a theoretic 21-day period), with the daily dose
and the number of days of assumption recorded. Importantly,
drugs administered as premedication before chemotherapy (e.g.
antiemetics, diuretics) did not have to be reported in the SC CRF.
All drugs assumed by patients have been coded according to the
anatomical therapeutic chemical (ATC) classification system
(World Health Organization Collaborating Centre for Drug
Statistics Methodology, 2002). This system has been recommended
for international studies on drug consumption by the WHO
Collaborating Centre for Drug Statistics Methodology. In the ATC
system, the drugs are divided into different groups according to
the system on which they act and their chemical, pharmacological
and therapeutic properties. Drugs are classified at five different
levels: 14 main groups (first level), two therapeutic/pharmacolo-
gical subgroups (second and third levels), a therapeutic/pharma-
cological/chemical subgroup (fourth level) and the chemical
substance (fifth level).
Analysis
In all the three studies analysed, instrumental restaging of the
patients was planned after three cycles of chemotherapy, and
patients with progressive disease did not receive any more
protocol treatment. So, in order to reduce the amount of missing
data and possible selection biases, analyses have been limited to
the period of time corresponding to the first three cycles
(theoretically 63 days). The number of drugs assumed by each
patient and frequencies within ATC categories were used for
analyses. The whole sample was taken into account for description
of the SC pattern. No analysis was carried out on dose and
frequency of drug assumption.
For comparative purposes, supportive drugs were grouped into
three categories, to reduce the number of statistical comparisons:
1. Drugs used against side effects of treatment: stomatologicals,
antiacids, antispasmodics, antiemetics, laxatives, antidiar-
rhoeals, antihaemorragics, antianaemics, anti-infectives, CSF.
2. Drugs used against tumour-related symptoms: anabolic agents,
appetite stimulants, antithrombotics, ACTH and corticoster-
oids, progestogens, anti-inflammatory drugs and analgesics,
drugs affecting demineralisation, antiepileptics, antiasthmatics,
expettorants and cough suppressants.
3. Drugs assumed against concomitant diseases: antidiabetics,
drugs for cardiovascular system, drugs for thyroid, drugs for
benign prostatic hypertrophy, psycholeptics and psychoana-
leptics.
This grouping procedure was somewhat arbitrary for some
categories (e.g. respiratory drugs could have been prescribed
because of concomitant chronic obstructive pulmonary disease
rather than tumour symptoms). Vitamins, integrators and mineral
supplements, which are not reasonably attributable to any
category, were described but not considered in statistical
comparisons.
Four questions were addressed in four different subgroups of
patients:
1. Does chemotherapy affect SC? – addressed in patients
randomised in the ELVIS trial (vinorelbine vs SC) (The ELVIS
group, 1999).
2. Does cisplatin-based chemotherapy affect SC? – addressed in
patients randomised in the GEMVIN3 study (cisplatin-based vs
noncisplatin-based chemotherapy) (Gridelli et al, 2003a).
3. Does performance status affect SC? – addressed comparing
patients with PS 0/1 vs patients with PS 2 from all the three
studies (The ELVIS group, 1999; Gridelli et al, 2003a,b). Owing
to the worse prognosis of PS2 patients and the corresponding
reduced number of cycles of chemotherapy, we limited this
analysis only to patients who had fulfilled all the three first
cycles, in the attempt of not underestimating the assumption of
supportive drugs among PS 2 subjects.
4. Does age affect SC? – addressed comparing patients receiving
gemcitabine plus vinorelbine in the GEMVIN3 study (Gridelli
et al, 2003a) (adults) vs those receiving the same chemotherapy
in the MILES study (Gridelli et al, 2003b) (elderly).
Within randomised comparisons (questions 1 and 2), differ-
ences in the number of assumed drugs were tested by the Wilcoxon
rank-sum test and differences in the use of different groups of
drugs were tested by w
2 test. Two-sided P-values less than 0.05 were
considered statistically significant. Questions 3 and 4 used patients
from different studies, thus some adjustment was needed. A
possible confounding effect, indeed, could arise from enrollment
bias among studies when assessing the role of PS and from a
different distribution of PS between adult and elderly subjects
when assessing the role of age. Thus, stratified Wilcoxon rank-sum
test and Mantel–Haenszel test (Mantel and Haenszel, 1959) were
carried out after stratification by treatment arm and PS category,
respectively (StatXact
r turbo, CYTEL software Corp. Cambridge,
MA, USA, 1992). Homogeneity assumption among strata was
previously tested by the Breslow–Day test (Breslow and Day,
1980).
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lRESULTS
Data on SC were available in 165 out of 191 patients (86%) in the
ELVIS study, in 655 out of 707 (93%) in the MILES study and in
365 out of 414 (88%) in the GEMVIN3 study. Overall, data were
available for 1185 patients out of the 1312 (90%) enrolled.
Principal characteristics of the 1185 analysed patients, according
to treatment arm, are described in Table 1. The median age was 74
years (range 69–85) in the ELVIS study, 73 years (64–86) in the
MILES study and 63 years (36–71) in the GEMVIN3 study. Most of
the patients were males (88, 83 and 83%, in the ELVIS, MILES and
GEMVIN3 trial, respectively). Performance status was equal to 0 in
19, 29 and 30%, equal to 1 in 56, 53 and 56%, and equal to 2 in 24,
18 and 13%, in ELVIS, MILES and GEMVIN3, respectively.
Description of SC
A total of 382 different products (corresponding to 265 different
active principles), representing 13 of the 14 ATC main groups,
were assumed: 136 mainly directed against treatment side effects
(95 active principles), 137 against tumour symptoms (88 active
principles) and 109 against concomitant diseases (82 active
principles). In addition, 21 products were vitamins, integrators
and mineral supplements.
Polypharmacotherapy was frequent: patients assumed 2.43
drugs on average; 898 (75.8%) assumed at least one supportive
drug, 709 (59.8%) two or more, 538 (45.4%) three or more. The
number of drugs assumed was similar across different treatment
arms (Figure 1).
The number of patients for the main ATC categories and some
subcategories are reported in Table 2. Gastrointestinal drugs (A,
45.7%), corticosteroids (H02, 33.4%), analgesics (N, 23.8%), anti-
inflammatory drugs (M, 18.7%) and drugs for respiratory system
(R, 16.5%) were the most frequently observed ATC codes.
Overall, 680 (57.4%), 633 (53.4%) and 199 (16.8%) patients
assumed at least one drug against tumour symptoms, treatment
side effects and concomitant diseases, respectively.
Does chemotherapy affect SC?
In the ELVIS study, comparing vinorelbine vs SC alone (Table 3),
131 out of 165 patients (79%) assumed at least one supportive
drug. The mean number of supportive drugs assumed in the
vinorelbine arm was 2.5 as compared with 2.8 in the SC alone arm
(P¼0.22). Drugs against side effects of treatment were assumed by
46% of patients in SC arm and 47% of those in the vinorelbine arm
(P¼0.89); this result is largely driven by antiacids presumably
prescribed to counteract gastric toxicity of corticosteroids and
other anti-inflammatory drugs. Drugs against symptoms were
assumed by 73% in the SC arm and 71% in the vinorelbine arm
(P¼0.70); drugs against concomitant diseases were assumed by
30% in the SC arm and 23% in the vinorelbine arm (P¼0.29). As
expected, haemopoietic growth factors were assumed only in the
chemotherapy arm, by 7% of patients.
Does cisplatin-based chemotherapy affect SC?
In the GEMVIN3 study, comparing cisplatin-based chemotherapy
with gemcitabine plus vinorelbine, 288 out of 365 patients (79%)
assumed at least one supportive drug. The mean number of
supportive drugs was higher in the cisplatin arm (2.6 vs 2.2,
P¼0.055). Drugs against treatment side effects were assumed by
66 and 61% of the patients (P¼0.33), drugs against symptoms by
57 and 53% (P¼0.42) and drugs against concomitant disease by 11
and 7% (P¼0.13), in the cisplatin and in the non-cisplatin arm,
respectively. As expected, relevant differences were observed for
antiemetics (41 vs 27%) and antianaemics (10 vs 4%), both more
frequent in the cisplatin arm (Table 4).
Does PS affect SC?
In the whole series of 1185 patients, 77% of PS 0 and 78% of PS 1
patients received three or more cycles of chemotherapy, as
compared to 60% of those with PS 2. This striking difference,
Table 1 Characteristics of the patients for whom information on supportive care (SC) was available, divided by trial and chemotherapy arm
Study ELVIS trial MILES trial GEMVIN3 trial
Arm SC alone Vinorelbine Vinorelbine Gemcitabine
Vinorelbine+
gemcitabine
Vinorelbine+
gemcitabine
CDDP-based
chemotherapy All patients
Median age (range) 74 (69–85) 74 (69–85) 73 (64–83) 73 (69–86) 73 (69–84) 63 (37–70) 64 (36–71) 71 (36–86)
Gender
Male 80 (89%) 65 (87%) 192 (87%) 179 (83%) 173 (79%) 150 (82%) 153 (85%) 992 (84%)
Female 10 (11%) 10 (13%) 28 (13%) 37 (17%) 46 (21%) 34 (18%) 28 (15%) 193 (16%)
PS
0 17 (19%) 15 (20%) 66 (30%) 64 (30%) 60 (27%) 56 (30%) 55 (30%) 333 (28%)
1 52 (58%) 41 (55%) 113 (51%) 113 (52%) 120 (55%) 103 (56%) 102 (56%) 644 (54%)
2 21 (23%) 19 (25%) 41 (19%) 39 (18%) 39 (18%) 25 (14%) 24 (13%) 208 (18%)
No of patients 90 75 220 216 219 184 181 1185
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Figure 1 Number of active principles assumed in different treatment
arms. Thiner and thicker line in the box: median and mean. Box hinges: 25–
75th percentiles; ends of the segments: 10–90th percentiles; dots: 5–95th
percentiles. SC¼supportive care; Vin¼vinorelbine; Gem¼gemcitabine;
P¼cisplatin.
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lpossibly due to worse prognosis or reduced tolerance to
chemotherapy, leads to underestimation of the amount of
supportive drugs consumed by PS 2 patients because of the
shorter exposure time. Thus, analysis of the effect of PS on SC was
limited to the 883 patients (759 with PS 0–1 and 124 with PS 2)
who had fulfilled all the three first cycles: the analysis is still
conservative because of the exclusion of the worst performing
patients, more frequent among those with PS 2.
Overall, 666 out of 883 patients (75%) assumed at least one
supportive drug. The mean number of supportive drugs assumed
by PS 0–1 patients was 2.3 as compared with 2.5 in the PS 2
patients (P¼0.41). Drugs against side effects of treatment were
Table 2 Drugs assumed by the 1185 patients, classified according to the WHO ATC system
ATC code Description Category No. of pts. (%)
A Alimentary tract and metabolism 542 (45.7)
A01 Stomatologicals SE 9 (0.8)
A02 Antacids and drugs for treatment of peptic ulcer SE 245 (20.7)
A03 Antispasmodic, anticholinergics and propulsives SE 148 (12.5)
A04 Antiemetics and antinauseants SE 193 (16.3)
A06 Laxatives SE 116 (9.8)
A07 Antidiarrhoeals and intestinal anti-infective agents SE 31 (2.6)
A10 Drugs used in diabetes CD 18 (1.5)
A11 Vitamins – 71 (6)
A12 Mineral supplements – 4 (0.3)
A14 Anabolic agents for systemic use TS 12 (1)
A15 Appetite stimulants TS 1 (0.1)
B Blood and blood-forming organs 150 (12.7)
B01 Antithrombotic agents TS 35 (3)
B02 Antihaemorrhagics SE 43 (3.6)
B03 Antianaemic preparations SE 54 (4.6)
C Cardiovascular system CD 141 (11.9)
D Dermatologicals CD 3 (0.3)
G Genitourinary system and sex hormones 4 (0.3)
G04 Drugs for benign prostatic hypertrophy CD 4 (0.3)
H Systemic hormonal preparations 420 (35.4)
H01AA ACTH TS 39 (3.3)
H02 Corticosteroids for systemic use TS 396 (33.4)
H03 Thyroid therapy CD 3 (0.2)
J General anti-infectives for systemic use 126 (10.6)
J01 Antibacterials for systemic use SE 114 (9.6)
J02 Antimycotics for systemic use SE 20 (1.7)
L Antineoplastic and immunomodulating agents 113 (9.5)
L02AB Progestogens TS 18 (1.5)
L03AA Colony-stimulating factors SE 97 (8.2)
M Muscoloskeletal agents 222 (18.7)
M01A Nonsteroidal anti-inflammatory drugs TS 200 (16.9)
M05B Drugs affecting mineralisation TS 34 (2.9)
N Nervous system (inch. Analgesics) 282 (23.8)
N02A Opioids TS 117 (9.9)
N02B Other analgesics and antipyretics TS 143 (12.1)
N03 Antiepileptics TS 6 (0.5)
N05 Psycoleptics CD 36 (3)
N06 Psycoanaleptics CD 15 (1.3)
N07C Antivertigo preparations CD 2 (0.2)
P Antiparasitic products CD 0 –
R Respiratory system 195 (16.5)
R03 Antiasthmatics TS 95 (8)
R05C Expettorants TS 47 (4)
R05D Cough suppressants TS 90 (7.6)
S Sensory organs CD 3 (0.3)
V Various – 23 (1.9)
SE¼against side effects of treatment; TS¼against tumour symptoms; CD¼against concomitant diseases.
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lassumed by 53 vs 58% (P¼0.24), drugs against symptoms by 56 vs
62% (P¼0.28), drugs against concomitant diseases by 15 and 23%
(P¼0.10), in patients with better and worse PS, respectively.
Patients with worse PS received antiacids and corticosteroids
much more frequently than PS 0–1 patients (Table 5).
Does age affect SC?
In order to avoid bias related to different chemotherapy, impact
of age on SC was studied by comparing 184 adult (o70 years) vs
219 elderly (X70 years) patients treated with the same chemo-
therapy (gemcitabine plus vinorelbine in the MILES and GEMVIN3
studies). Overall, 306 out of 403 patients (76%) received
at least one supportive drug. The mean number of supportive
drugs assumed by adult patients was 2.2, and that in the elderly
patients 2.3 (P¼0.75). As shown in Table 6, drugs against
treatment side effects were assumed by 61 vs 55% (P¼0.22),
drugs against symptoms by 53 vs 52% (P¼0.76), drugs against
concomitant diseases by 7 vs 20% (Po0.0001), in adults
and elderly patients, respectively. Among drugs against toxicity,
use of antiemetics was more frequent among adults than elderly
people (27 vs 12%). Among drugs for concomitant diseases,
cardiovascular drugs were more frequently used in elderly than
adults (16 vs 3%).
DISCUSSION
A significant proportion of the patients included in the present
analysis assumed three or more different drugs in addition to
chemotherapy. Polypharmacotherapy, defined as the simultaneous
assumption of many drugs, can produce noxious effects
(Alderman, 2000). Among the several problems related to
polypharmacotherapy, one of the most frequently addressed is
the higher number of adverse drug reactions and drug–
drug interactions, which can become crucial with drugs with a
narrow therapeutic index, that is, small difference between
therapeutic and toxic doses. Another problem is treatment
compliance; the more drugs a patient takes, the harder it is
to keep their administration correct. For example, in a study of
patients with either diabetes or congestive heart failure, among
patients taking one drug, 15% made errors, while those taking
two or three drugs had a 25% error rate and over 35% of those
taking four or more drugs made errors (Hulka et al, 1975). In
a large study analysing the causes of medical emergencies in
elderly people (Malhotra et al, 2001), there was a significant
contribution of adverse drug reactions, accounting for 6.7% of
the events, and noncompliance with medications, accounting
for another 7.6%. Polypharmacotherapy was associated with
an increased risk of admission both for adverse reactions and
Table 3 Does chemotherapy affect supportive care (SC)?
SC alone
(n¼90)
Vinorelbine
(n¼75) P
a
Drugs against treatment side effects 41 (46%) 35 (47%) 0.89
A01 Stomatologicals 0 0
A02 Antacids 29 (32%) 14 (19%)
A03 Antispasmodics 4 (4%) 5 (7%)
A04 Antiemetics 0 2 (3%)
A06 Laxatives 4 (4%) 6 (8%)
A07 Antidiarrhoeals 1 (1%) 1 (1%)
B02 Antihaemorrhagics 4 (4%) 7 (9%)
B03 Antianaemics 1 (1%) 3 (4%)
J01 Antibacterials for systemic use 10 (11%) 6 (8%)
J02 Antimycotics for systemic use 0 1 (1%)
L03AA Colony-stimulating factors 0 5 (7%)
Drugs against tumour symptoms 66 (73%) 53 (71%) 0.70
A14 Anabolic agents for systemic use 3 (3%) 3 (4%)
A15 Appetite stimulants 1 (1%) 0
B01 Antithrombotic agents 0 1 (1%)
H01AA ACTH 7 (8%) 0
H02 Corticosteroids for systemic use 45 (50%) 32 (43%)
L02AB Progestogens 2 (2%) 3 (4%)
M01A Nonsteroidal anti-inflammatory drugs 26 (29%) 14 (19%)
M05B Drugs affecting mineralisation 5 (6%) 1 (1%)
N02A Opioids 16 (18%) 9 (12%)
N02B Other analgesics and antipyretics 12 (13%) 8 (11%)
N03 Antiepileptics 0 0
R03 Antiasthmatics 8 (9%) 5 (7%)
R05C Expettorants 10 (11%) 9 (12%)
R05D Cough suppressants 14 (16%) 11 (15%)
Drugs against concomitant diseases 27 (30%) 17 (23%) 0.29
A10 Antidiabetics 1 (1%) 0
C Cardiovascular system 17 (19%) 12 (16%)
G04 Drugs for prostatic hypertrophy 1 (1%) 0
H03 Drugs for thyroid 0 0
N05 Psycholeptics 8 (9%) 5 (7%)
N06 Psychoanaleptics 2 (2%) 0
N07C Antivertigo preparations 1 (1%) 0
Elderly patients randomised in the ELVIS trial. The table shows the number
(percentage) of patients assuming at least one drug of each category during the first
63 days of treatment.
aw
2 test.
Table 4 Does cisplatin-based chemotherapy affect SC?
Cisplatin-
based
(N¼181)
Non-
cisplatin
(N¼184) P
a
Drugs against treatment side effects 120 (66%) 113 (61%) 0.33
A01 Stomatologicals 0 0
A02 Antacids 39 (22%) 39 (21%)
A03 Antispasmodics 28 (15%) 31 (17%)
A04 Antiemetics 75 (41%) 49 (27%)
A06 Laxatives 14 (8%) 18 (10%)
A07 Antidiarrhoeals 9 (5%) 6 (3%)
B02 Antihaemorrhagics 2 (1%) 10 (5%)
B03 Antianaemics 19 (10%) 8 (4%)
J01 Antibacterials for systemic use 15 (8%) 18 (10%)
J02 Antimycotics for systemic use 4 (2%) 4 (2%)
L03AA Colony-stimulating factors 23 (13%) 19 (10%)
Drugs against tumour symptoms 104 (57%) 98 (53%) 0.42
A14 Anabolic agents for systemic use 2 (1%) 2 (1%)
A15 Appetite stimulants 0 0
B01 Antithrombotic agents 7 (4%) 3 (2%)
H01AA ACTH 2 (1%) 3 (2%)
H02 Corticosteroids for systemic use 70 (39%) 61 (33%)
L02AB Progestogens 3 (2%) 0
M01A Nonsteroidal anti-inflammatory drugs 38 (21%) 26 (14%)
M05B Drugs affecting mineralisation 8 (4%) 5 (3%)
N02A Opioids 19 (10%) 10 (5%)
N02B Other analgesics and antipyretics 18 (10%) 21 (11%)
N03 Antiepileptics 0 2 (1%)
R03 Antiasthmatics 9 (5%) 15 (8%)
R05C Expettorants 4 (2%) 3 (2%)
R05D Cough suppressants 9 (5%) 11 (6%)
Drugs against concomitant diseases 20 (11%) 12 (7%) 0.13
A10 Antidiabetics 4 (2%) 1 (1%)
C Cardiovascular system 16 (9%) 5 (3%)
G04 Drugs for prostatic hypertrophy 0 1 (1%)
H03 Drugs for thyroid 0 1 (1%)
N05 Psycholeptics 2 (1%) 2 (1%)
N06 Psychoanaleptics 1 (2%) 2 (1%)
N07C Antivertigo preparations 0 0
Adult Italian patients randomized in the GEMVIN3 study. The table shows the
number (percentage) of patients assuming at least one drug of each category during
the first 63 days of treatment
aw
2 test.
Supportive care in advanced NSCLC patients
M Di Maio et al
1017
British Journal of Cancer (2003) 89(6), 1013–1021 & 2003 Cancer Research UK
C
l
i
n
i
c
a
lnoncompliance. Last but not least, pharmacoeconomic considera-
tions should not be forgotten, especially when prescribing drugs
characterised by high costs.
We divided supportive drugs into three categories: drugs against
treatment side effects, against tumour symptoms and against
concomitant diseases. More than half of the patients assumed
drugs of the first two groups, while one-fifth assumed drugs
against concomitant diseases. Our classification could be debatable
for some drugs that can be prescribed with different purposes, for
example, antibiotics in the SC arm of the ELVIS trial (see Table 3)
that were probably prescribed to counteract infectious episodes
typical of chronic obstructive pulmonary disease frequently
associated with lung cancer.
Studying factors affecting the use of supportive drugs we found
four main results: (i) a relatively low-toxic chemotherapeutic agent
(vinorelbine) does not produce substantial variations in the SC
pattern; (ii) a more toxic cisplatin-based treatment requires an
overall higher number of supportive drugs, and exposes a higher
rate of patients to antiemetics and antianaemics; (iii) a deterio-
rated performance status is associated with an increased exposure
to corticosteroids and a general tendency to an increased use of
supportive drugs; (iv) elderly patients require drugs against
concomitant diseases significantly more than adults and are less
exposed to antiemetics.
As for the first two points, it is a common opinion that side
effects of chemotherapy impair quality of life and require
assumption of drugs against toxicity. Impact of chemotherapy
on quality of life was ruled out by the primary analysis of the
ELVIS study showing an overall improvement of quality of life
(The ELVIS group, 1999), and it appears now that there are no
statistically significant differences in the SC pattern, with the
obvious exception on CSFs, not used in the SC arm. The similar
rate of patients exposed to antiacid in the two arms is clearly
related to the prevention of gastric side effects of corticosteroids,
assumed by about half of the patients. Of course, this result is
driven by the use of single agent vinorelbine, a drug known for its
good tolerability and the relatively low incidence of side effects. In
fact, a difference in the mean number of drugs assumed by the
patients was found between the arm receiving cisplatin-based
chemotherapy and the arm receiving chemotherapy without
cisplatin, in the GEMVIN3 trial. The higher incidence of side
effects following cisplatin administration (e.g. nausea/vomiting
among nonhaematologic toxicities, anaemia among haematologic
toxicities) produced higher assumption of several drug categories
Table 5 Does performance status (PS) affect SC?
PS 0/1
(N¼759)
PS 2
(N¼124) P
a
Drugs against treatment side effects 406 (53%) 72 (58%) 0.24
A01 Stomatologicals 8 (1%) 1 (1%)
A02 Antacids 141 (19%) 33 (27%)
A03 Antispasmodics 99 (13%) 11 (9%)
A04 Antiemetics 141 (19%) 17 (14%)
A06 Laxatives 73 (10%) 17 (14%)
A07 Antidiarrhoeals 20 (3%) 2 (2%)
B02 Antihaemorrhagics 27 (4%) 5 (4%)
B03 Antianaemics 41 (5%) 5 (4%)
J01 Antibacterials for systemic use 68 (9%) 8 (6%)
J02 Antimycotics for systemic use 13 (2%) 2 (2%)
L03AA Colony-stimulating factors 71 (9%) 7 (6%)
Drugs against tumour symptoms 424 (56%) 77 (62%) 0.28
A14 Anabolic agents for systemic use 8 (1%) 0
A15 Appetite stimulants 1 (o1%) 0
B01 Antithrombotic agents 28 (4%) 0
H01AA ACTH 26 (3%) 7 (6%)
H02 Corticosteroids for systemic use 230 (30%) 52 (42%)
L02AB Progestogens 11 (1%) 1 (1%)
M01A Nonsteroidal anti-inflammatory drugs 122 (16%) 24 (19%)
M05B Drugs affecting mineralisation 18 (2%) 4 (3%)
N02A Opioids 64 (8%) 13 (10%)
N02B Other analgesics and antipyretics 97 (13%) 20 (16%)
N03 Antiepileptics 4 (1%) 0
R03 Antiasthmatics 61 (8%) 9 (7%)
R05C Expettorants 27 (4%) 5 (4%)
R05D Cough suppressants 58 (8%) 14 (11%)
Drugs against concomitant diseases 116 (15%) 28 (23%) 0.10
A10 Antidiabetics 12 (2%) 0
C Cardiovascular system 80 (11%) 20 (16%)
G04 Drugs for prostatic hypertrophy 2 (o1%) 0
H03 Drugs for thyroid 2 (o1%) 1 (1%)
N05 Psycholeptics 22 (3%) 5 (4%)
N06 Psychoanaleptics 9 (1%) 2 (2%)
N07C Antivertigo preparations 2 (o1%) 0
Patients with PS 0/1 vs patients with PS 2 in all three studies. The table shows the
number (percentage) of patients assuming at least one drug of each category during
the first 63 days of treatment. Only patients receiving three or more cycles of
chemotherapy are considered.
aMantel Haenszel test stratified by treatment arm.
Table 6 Does age affect SC?
Adult
patients
(N¼184)
Elderly
patients
(N¼219) P
a
Drugs against treatment side effects 113 (61%) 120 (55%) 0.22
A01 Stomatologicals 0 4 (2%)
A02 Antacids 39 (21%) 41 (19%)
A03 Antispasmodics 31 (17%) 27 (12%)
A04 Antiemetics 49 (27%) 26 (12%)
A06 Laxatives 18 (10%) 29 (13%)
A07 Antidiarrhoeals 6 (3%) 7 (3%)
B02 Antihaemorrhagics 10 (5%) 7 (3%)
B03 Antianaemics 8 (4%) 12 (5%)
J01 Antibacterials for systemic use 18 (10%) 21 (10%)
J02 Antimycotics for systemic use 4 (2%) 3 (1%)
L03AA Colony-stimulating factors 19 (10%) 22 (10%)
Drugs against tumour symptoms 98 (53%) 113 (52%) 0.76
A14 Anabolic agents for systemic use 2 (1%) 0
A15 Appetite stimulants 0 0
B01 Antithrombotic agents 3 (2%) 8 (4%)
H01AA ACTH 3 (2%) 14 (6%)
H02 Corticosteroids for systemic use 61 (33%) 60 (27%)
L02AB Progestogens 0 3 (1%)
M01 A Nonsteroidal anti-inflammatory drugs 26 (14%) 28 (13%)
M05B Drugs affecting mineralisation 5 (3%) 5 (2%)
N02A Opioids 10 (5%) 20 (9%)
N02B Other analgesics and antipyretics 21(11%) 26 (12%)
N03 Antiepileptics 2 (1%) 1 (o1%)
R03 Antiasthmatics 15 (8%) 15 (7%)
R05C Expettorants 3 (2%) 3 (1%)
R05D Cough suppressants 11 (6%) 16 (7%)
Drugs against concomitant diseases 12 (7%) 44 (20%) 0.0001
A10 Antidiabetics 1 (1%) 1 (o1%)
C Cardiovascular system 5 (3%) 35 (16%)
G04 Drugs for benign prostatic hypertrophy 1 (1%) 1 (o1%)
H03 Drugs for thyroid 1 (1%) 1 (o1%)
N05 Psycholeptics 2 (1%) 6 (3%)
N06 Psychoanaleptics 2 (1%) 2 (1%)
N07C Antivertigo preparations 0 1 (o1%)
Patients receiving gemcitabine plus vinorelbine in the GEMVIN3 study (adult patients)
vs those receiving the same chemotherapy in the MILES study (elderly patients). The
table shows the number (percentage) of patients assuming at least one drug of each
category during the first 63 days of treatment.
aMantel–Haenszel test stratified by PS
category.
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the combination of two less toxic drugs, gemcitabine and
vinorelbine.
Performance status has an important prognostic role in patients
with advanced NSCLC (Ando et al, 2001). A worse PS can be
related to pre-existing comorbid conditions, or to pain and other
cancer symptoms. Although not reaching a statistically significant
difference in the mean number of drugs assumed, a higher intake
by patients with worse PS was observed for several drugs against
concomitant diseases and cancer symptoms, particularly for
corticosteroids. However, our conservative strategy of comparing
only patients who actually received three cycles does probably
decrease the differences, excluding patients with worse health
status among those with PS 2.
As for the impact of age on SC, the higher assumption of
drugs for cardiovascular system among elderly patients reflects
the higher frequency of comorbidities among these patients
(Repetto and Balducci, 2002). The finding that antiemetic
agents are more frequently used in younger than older patients,
during the same chemotherapy, was unexpected. It is not
fully justifiable with incidence of vomiting in the two studies:
overall 38% of elderly and 46% of adult patients suffered any
grade vomiting, with 8 vs 11% suffering grade 2, respectively,
and only 1% grade 3 in both groups. With the exception of
the higher incidence of acute dystonic reactions in younger
patients, age should not significantly predict the incidence of
chemotherapy-induced nausea and vomiting or the response
to antiemetic treatment. Some studies have shown better control
in older patients, whereas others have reported little difference
among age groups (Berger and Clark-Snow, 1997). Part of the
large difference observed may probably be explained with
reluctance in prescribing antiemetics to elderly patients, for whom
these drugs could be less manageable and with higher incidence of
toxicity.
As this is a secondary analysis of three prospective trials pooled
together, some consideration need to be given on the quality of the
evidences found. The first two questions (the impact of
chemotherapy vs SC alone and the impact of cisplatin-based
chemotherapy) were each addressed within a specific randomised
study; in both of these studies, data on SC were available for most
of the patients. Of course, although an a priori hypotheses had not
been stated and no power calculation had been carried out as for
the questions raised in this paper, statistical comparisons
presented here can be considered correct, thanks to the
randomised design. The two questions regarding the impact of
patients’ PS and age have been addressed across different
randomised studies; thus, they represent indirect explorative
subgroup comparisons and their results should be treated with
caution. Notwithstanding these limitations, evidences presented
here are among the strongest available in the literature. Indeed,
descriptions of SC patterns in association with chemotherapy
practically do not exist, to the best of our knowledge; in addition,
while much interest has been paid to specific drug classes (e.g.
antiemetics, CSFs and antibiotics), less attention has been paid to
polypharmacotherapy, and to the degree of cytotoxic chemother-
apy, and patients’ characteristics do affect the overall burden of SC.
This is disturbing, considering that oncologists continuously face
empiric integration of antineoplastic and supportive drugs.
Further studies aimed at a ‘wide-angle’ treatment approach are
awaited, which could probably improve our ability of correctly
managing cancer patients.
As a final consideration, we believe that three major messages
come from our findings: (i) more attention should be paid in
clinical practice and research to drug interactions, frequently not
well studied and potentially dangerous; (ii) choosing different
cytotoxic drugs translates into different levels of cost and drug
interaction risk in SC patterns; these consequences should be
considered in treatment choice both at singular and population
levels; (iii) there are subgroups of patients for whom the issue of
SC looks of paramount importance not only because of the limited
efficacy of antineoplastic drugs but also for the higher risk of drug
interactions. Nevertheless, SC is usually neglected as a matter of
research, even in these high-risk patient subgroups.
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